ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...

(Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering ... in children aged 1 to <18 years with PK deficiency who are not regularly transfused achieved ...

USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to ...

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Pyruknd won its first approval in 2022 for pyruvate kinase (PK) deficiency, marking the first drug approved to treat the disease. The vaccine was previously approved for use in females who are 9 ...

When you buy through links on our articles, Future and its syndication partners may earn a commission.

The aircraft carrier USS Harry S. Truman was involved in a collision at sea with a merchant vessel near Port Said, Egypt, the ...